اخبار و اعلانات

 آمار

تعداد نشریات418
تعداد شماره‌ها9,997
تعداد مقالات83,560
تعداد مشاهده مقاله77,801,347
تعداد دریافت فایل اصل مقاله54,843,963
Li, Luan, Feng, Yuxu, Li, Chenchen, Liu, Siwen, Yan, Fei, Zhu, Jingni, Li, Xiaoyou, Li, Sheng. (1400). Evaluation of the efficacy and safety of FOLFIRINOX or albumin-bound paclitaxel in combination with S-1 in patients with pancreatic cancer. نشریه علمی پژوهشی دانشگاه آزاد اسلامی, 13(1), 12-19. doi: 10.47176/IJIC.13.1.2
Luan Li; Yuxu Feng; Chenchen Li; Siwen Liu; Fei Yan; Jingni Zhu; Xiaoyou Li; Sheng Li. "Evaluation of the efficacy and safety of FOLFIRINOX or albumin-bound paclitaxel in combination with S-1 in patients with pancreatic cancer". نشریه علمی پژوهشی دانشگاه آزاد اسلامی, 13, 1, 1400, 12-19. doi: 10.47176/IJIC.13.1.2
Li, Luan, Feng, Yuxu, Li, Chenchen, Liu, Siwen, Yan, Fei, Zhu, Jingni, Li, Xiaoyou, Li, Sheng. (1400). 'Evaluation of the efficacy and safety of FOLFIRINOX or albumin-bound paclitaxel in combination with S-1 in patients with pancreatic cancer', نشریه علمی پژوهشی دانشگاه آزاد اسلامی, 13(1), pp. 12-19. doi: 10.47176/IJIC.13.1.2
Li, Luan, Feng, Yuxu, Li, Chenchen, Liu, Siwen, Yan, Fei, Zhu, Jingni, Li, Xiaoyou, Li, Sheng. Evaluation of the efficacy and safety of FOLFIRINOX or albumin-bound paclitaxel in combination with S-1 in patients with pancreatic cancer. نشریه علمی پژوهشی دانشگاه آزاد اسلامی, 1400; 13(1): 12-19. doi: 10.47176/IJIC.13.1.2

Evaluation of the efficacy and safety of FOLFIRINOX or albumin-bound paclitaxel in combination with S-1 in patients with pancreatic cancer

International Journal of Industrial Chemistry
دوره 13، شماره 1، خرداد 2022، صفحه 12-19    اصل مقاله (548.61 K)
نوع مقاله: research article
شناسه دیجیتال (DOI): 10.47176/IJIC.13.1.2
نویسندگان
Luan Li1؛ Yuxu Feng2؛ Chenchen Li1؛ Siwen Liu1؛ Fei Yan1؛ Jingni Zhu1؛ Xiaoyou Li* 3؛ Sheng Li1
1Department of Medical Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China
2Department of Orthopaedics, Pukou Central Hospital, PuKou Branch Hospital of Jiangsu Province Hospital, Nanjing, Jiangsu, People’s Republic of China
3Department of Medical Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China
چکیده
To investigate the clinical efficacy and safety of FOLFIRINOX or albumin-bound paclitaxel (Abraxane) combined with S-1 after radical pancreatic cancer surgery.
A total of 133 patients who underwent adjuvant chemotherapy with the FOLFIRINOX (60 cases) or Abraxane combined with S-1 (73 cases) after radical resection pancreatic cancer were screened. According to the follow-up data, recurrence and metastasis, chemotherapy adverse reactions (nausea, vomiting, loss of appetite, leukopenia, thrombocytopenia, anemia, neurotoxicity, diarrhea), survival rate (OS), progression-free survival (PFS) and other indicators were collected to evaluate the efficacy and safety of the two chemotherapy regimens.
There was significant difference of metastatic tumor site between both groups (P<0.001). The cases of DCR in the Abraxane + S-1 group were higher compared to the FOLFIRINOX group (P<0.001). The occurrence of adverse events was significantly lower in Abraxane + S-1 group during I-II AE compared with the FOLFIRINOX group. However, there was no significant difference in the AE during III-IV between two groups (P>0.05). The OS (HR=1.872, P=0.005) and PFS (HR=1.931, P=0.003) in Abraxane + S-1 group were significantly higher than those in the FOLFIRINOX group.
Adjuvant chemotherapy with Abraxane combined with S-1 regimen in patients with pancreatic cancer resection prolonged OS and PFS, improved DCR, with the overall adverse reactions safe and manageable compared with the FOLFIRINOX regimen.
کلیدواژه‌ها
FOLFIRINOX؛ albumin-bound paclitaxel؛ S-1؛ pancreatic cancer
آمار
تعداد مشاهده مقاله: 47
تعداد دریافت فایل اصل مقاله: 40


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب